Compare Cassava Sciences Inc (FLNA) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.25 (market cap $45.27B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 851.9× Cassava Sciences Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TTWO | |
|---|---|---|
Market Cap | $53.14M | $45.27B |
Sector | Health | Media |
52-Week High | $4.64 | $262.29 |
52-Week Low | $1.09 | $189.69 |
Enterprise Value | -$33.43M | $46.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Take-Two Interactive (TTWO) trades at $242.40, up 2.27% with bullish technical signals and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.563 estimate. Recent news highlights Grand Theft Auto VI pre-orders beginning June 25, 2026, priced at $79.99, driving positive sentiment. Despite a negative net income margin of -4.48% in 2025, revenue grew to $5.63B, and the company maintains a solid cash position of $1.47B.
The outlook is optimistic due to GTA VI's upcoming launch, with analysts projecting a consensus price target of $302.50. Risks include high debt levels and profitability challenges, but institutional bullishness and technical strength suggest potential upside. Investors should monitor execution on game launches and margin improvement for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
